Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the9 preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance and an antioxidant, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, butylated hydroxyanisole is the preferred antioxidant. Additional preferred excipients include, for example, microcrystalline cellulose, sucrose, mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance and an antioxidant, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, butylated hydroxyanisole is the preferred antioxidant. Additional preferred excipients include, for example, microcrystalline cellulose, sucrose, mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance and an antioxidant, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, butylated lydroxyanisole is the preferred antioxidant. Additional preferred excipients include, for example, microcrystalline cellulose, sucrose, mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: A blower noise reducing device for use in a blower having a blower housing defining a volute, a discharge opening through the blower housing, and a discharge nozzle connected over the discharge opening. The blower noise reducing device comprises a moving air deflecting member having a generally triangular cross-section, a first end representing a base of the generally triangular cross-section, a second end representing an apex of the generally triangular cross-section, a first side for mounting against a wall of the discharge nozzle (at a connecting point between the discharge opening and the discharge nozzle), and a second and opposite side for protruding into the discharge opening and discharge nozzle when the first side is mounted against the wall of the discharge nozzle, thereby reducing noise causing characteristics of air being moved by deflecting such moving air in a predetermined manner.

Abstract: An office machine including a machine frame defining an operating environment, operating components mounted within the frame and requiring environmental conditioning such as cooling and cleaning, and an air blower for conditioning the operating environment within the frame. The air blower includes a housing having a housing wall defining an air path and an air discharge opening, a discharge nozzle, mounted over the discharge opening for directing air being discharged away from the housing, a pinch point formed between the housing wall and the discharge nozzle at the discharge opening, an air moving assembly including a rotatable impeller mounted within the housing for drawing air into the air path, and a blower noise reducing device on the pinch point for minimizing air stagnation at the pinch point.

Abstract: A modular leakage current detector and machine interrupter including a sense module for detecting ground fault currents in excess of a given value, the sense module including circuitry to provide an interrupt signal, a circuit interrupter interconnected to the sense module to disconnect power to the machine upon receipt of the interrupt signal, and a test and control module electrically connected to the sense module, the test and control module providing a fault signal to periodically test the operability of and reset the modular leakage current detector and machine interrupter.

Abstract: A xerographic CRU (Customer Relpaceable Unit) for an electrophotographic printing machine. The xerographic CRU has retaining features and cooperates with a drive module with certain retractable features that allow the insertion and removal of the CRU without causing damage to the photoreceptor and other critical subsystems. The unit further has many locating members for other subsystems so that critical tolerances are maintained. An interface with a single handle assembly retracts/unlocks and extends/locks the drive module and the associated CRU subsystems into an operative position. The CRU also has electrical and drive connections for the cleaning system, the charging system and transfer/detack.

Abstract: A developer housing of an electrostatographic reproducing machine of the type using a magnet roll is provided with two openings in at least one of its side walls. The first of these holes is located at the high pressure portion of the housing, and the second of the holes is located at the low pressure end of the housing. The holes are interconnected by a pneumatic duct. A pressure differential is created as vane-like whiskers of developer are rotated about the magnet roll. The duct neutralizes these pressure differentials within the developer housing, thus preventing toner from being blown out of the developer housing.

Abstract: A multifunction blower in which a common housing is employed to both increase and decrease the pressure of incoming air in separate chambers thereof. The increase and decrease in air pressure is adjustable by changing the impellers of the pressure and vacuum assemblies used therein.